Omeros Corporation (NASDAQ: OMER) has recently received a number of price target changes and ratings updates:

  • 11/9/2017 – Omeros Corporation was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. “
  • 11/8/2017 – Omeros Corporation is now covered by analysts at HC Wainwright. They set a “buy” rating and a $30.00 price target on the stock.
  • 11/6/2017 – Omeros Corporation had its “buy” rating reaffirmed by analysts at Maxim Group. They now have a $24.00 price target on the stock. They wrote, “Omeros announced that extended follow-up data from patients with immunoglobulin A (IgA) nephropathy treated with OMS721 were presented on November 4, 2017 at the American Society of Nephrology (ASN) Meeting in New Orleans. These data describe up to one-year follow-up of patients treated with OMS721 in the glomerulonephropathy Phase 2 clinical trial. OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin- associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system.””
  • 11/2/2017 – Omeros Corporation was downgraded by analysts at Cowen and Company from an “outperform” rating to a “market perform” rating.
  • 10/27/2017 – Omeros Corporation had its “buy” rating reaffirmed by analysts at Maxim Group. They now have a $24.00 price target on the stock.
  • 10/25/2017 – Omeros Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. “
  • 10/20/2017 – Omeros Corporation was given a new $24.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock. They wrote, “Omeros announced successful treatment with OMS721 of a patient having both stem cell transplant-associated thrombotic microangiopathy (HCT-TMA) and graft vs. host disease (GvHD). The data were presented at the European Society for Blood and Marrow Transplantation (EBMT) Crash Course on Diagnosis and Treatment of Noninfectious Complications after HCT.””
  • 10/19/2017 – Omeros Corporation was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $22.00 price target on the stock. According to Zacks, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. “

Omeros Corporation (OMER) opened at $18.81 on Tuesday. The company has a debt-to-equity ratio of 8.99, a current ratio of 4.77 and a quick ratio of 4.74. Omeros Corporation has a fifty-two week low of $8.71 and a fifty-two week high of $27.09.

Omeros Corporation (NASDAQ:OMER) last released its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.18. The firm had revenue of $21.66 million for the quarter, compared to the consensus estimate of $17.82 million. During the same quarter in the previous year, the business posted ($0.34) EPS. The firm’s revenue for the quarter was up 91.9% compared to the same quarter last year. analysts forecast that Omeros Corporation will post -1.32 earnings per share for the current fiscal year.

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.